Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR BATs and LIFU in Newly Diagnosed Glioblastoma
NCT07343986Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of EGFR BATs in glioblastoma (GBM) (2 arms), sponsored by University of Virginia. Primary endpoints: Dose-Limiting Toxicities at 8 weeks, Treatment Feasibility at 8 weeks and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
EGFR BATs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07343986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343986.